Amedisys [AMED] vs HCA Healthcare [HCA] Detailed Stock Comparison
Amedisys
NASDAQ
Loading...
HCA Healthcare
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Amedisys wins in 3 metrics, HCA Healthcare wins in 16 metrics, with 0 ties. HCA Healthcare appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Amedisys | HCA Healthcare | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 38.63 | 16.02 | HCA Healthcare |
| Price-to-Book Ratio | 2.65 | -72.79 | HCA Healthcare |
| Debt-to-Equity Ratio | 35.34 | -37.45 | HCA Healthcare |
| PEG Ratio | 19.43 | 15.54 | HCA Healthcare |
| EV/EBITDA | 13.52 | 9.37 | HCA Healthcare |
| Profit Margin (TTM) | 3.56% | 8.21% | HCA Healthcare |
| Operating Margin (TTM) | 11.70% | 15.95% | HCA Healthcare |
| EBITDA Margin (TTM) | 11.70% | 15.95% | HCA Healthcare |
| Return on Equity | 6.67% | 13,631.68% | HCA Healthcare |
| Return on Assets (TTM) | 6.52% | 11.84% | HCA Healthcare |
| Free Cash Flow (TTM) | $214.29M | $5.64B | HCA Healthcare |
| Dividend Yield | N/A | 0.54% | N/A |
| 1-Year Return | 3.24% | 5.74% | HCA Healthcare |
| Price-to-Sales Ratio (TTM) | 1.36 | 1.23 | HCA Healthcare |
| Enterprise Value | $3.42B | $135.84B | HCA Healthcare |
| EV/Revenue Ratio | 1.42 | 1.87 | Amedisys |
| Gross Profit Margin (TTM) | 43.96% | 40.97% | Amedisys |
| Revenue per Share (TTM) | $73 | $292 | HCA Healthcare |
| Earnings per Share (Diluted) | $2.57 | $23.82 | HCA Healthcare |
| Beta (Stock Volatility) | 0.90 | 1.40 | Amedisys |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Amedisys vs HCA Healthcare Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Amedisys | 0.06% | 2.47% | 3.35% | 6.03% | 9.68% | 11.05% |
| HCA Healthcare | 2.22% | 6.90% | 1.06% | 7.82% | 19.91% | 28.16% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Amedisys | 3.24% | -17.52% | -56.18% | 122.39% | 322.79% | 231.32% |
| HCA Healthcare | 5.74% | 74.34% | 183.87% | 317.52% | 1,126.25% | 1,126.25% |
Performance & Financial Health Analysis: Amedisys vs HCA Healthcare
| Metric | AMED | HCA |
|---|---|---|
| Market Information | ||
| Market Cap | $3.27B | $89.29B |
| Market Cap Category | Mid cap | Large cap |
| 10 Day Avg. Volume | 719,530 | 1,426,893 |
| 90 Day Avg. Volume | 516,367 | 1,471,124 |
| Last Close | $100.94 | $381.61 |
| 52 Week Range | $82.15 - $100.99 | $289.98 - $417.14 |
| % from 52W High | -0.05% | -8.52% |
| All-Time High | $325.12 (Jan 25, 2021) | $417.14 (Oct 14, 2024) |
| % from All-Time High | -68.95% | -8.52% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.05% | 0.06% |
| Quarterly Earnings Growth | -0.13% | 0.13% |
| Financial Health | ||
| Profit Margin (TTM) | 0.04% | 0.08% |
| Operating Margin (TTM) | 0.12% | 0.16% |
| Return on Equity (TTM) | 0.07% | 136.32% |
| Debt to Equity (MRQ) | 35.34 | -37.45 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $37.48 | $-18.61 |
| Cash per Share (MRQ) | $10.26 | $4.45 |
| Operating Cash Flow (TTM) | $239.42M | $11.93B |
| Levered Free Cash Flow (TTM) | $300.69M | $5.59B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 0.54% |
| Last 12-Month Dividend | N/A | $2.04 |
Valuation & Enterprise Metrics Analysis: Amedisys vs HCA Healthcare
| Metric | AMED | HCA |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 38.63 | 16.02 |
| Forward P/E | 19.43 | 15.54 |
| PEG Ratio | 19.43 | 15.54 |
| Price to Sales (TTM) | 1.36 | 1.23 |
| Price to Book (MRQ) | 2.65 | -72.79 |
| Market Capitalization | ||
| Market Capitalization | $3.27B | $89.29B |
| Enterprise Value | $3.42B | $135.84B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.42 | 1.87 |
| Enterprise to EBITDA | 13.52 | 9.37 |
| Risk & Other Metrics | ||
| Beta | 0.90 | 1.40 |
| Book Value per Share (MRQ) | $37.48 | $-18.61 |
Financial Statements Comparison: Amedisys vs HCA Healthcare
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | AMED | HCA |
|---|---|---|
| Revenue/Sales | $621.86M | $18.61B |
| Cost of Goods Sold | $348.47M | $10.98B |
| Gross Profit | $273.39M | $7.62B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | $72.74M | $2.97B |
| EBITDA | $97.35M | $3.85B |
| Pre-Tax Income | $48.33M | $2.42B |
| Income Tax | $19.27M | $524.00M |
| Net Income (Profit) | $29.05M | $1.89B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | AMED | HCA |
|---|---|---|
| Cash & Equivalents | $337.30M | $1.06B |
| Total Current Assets | $662.20M | $16.26B |
| Total Current Liabilities | $488.36M | $13.63B |
| Long-Term Debt | $386.83M | $42.92B |
| Total Shareholders Equity | $1.27B | $-438.00M |
| Retained Earnings | $880.25M | $-3.16B |
| Property, Plant & Equipment | $229.50M | $65.81B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | AMED | HCA |
|---|---|---|
| Operating Cash Flow | $75.50M | $2.65B |
| Capital Expenditures | $-696,000 | $-991.00M |
| Free Cash Flow | $66.29M | $660.00M |
| Debt Repayment | N/A | $-3.90B |
| Common Stock Repurchase | N/A | $-2.51B |
Short Interest & Institutional Ownership Analysis
| Metric | AMED | HCA |
|---|---|---|
| Shares Short | 2.24M | 3.89M |
| Short Ratio | 4.66 | 2.67 |
| Short % of Float | 0.07% | 0.02% |
| Average Daily Volume (10 Day) | 719,530 | 1,426,893 |
| Average Daily Volume (90 Day) | 516,367 | 1,471,124 |
| Shares Outstanding | 32.78M | 249.98M |
| Float Shares | 32.24M | 161.55M |
| % Held by Insiders | 0.02% | 0.31% |
| % Held by Institutions | 0.93% | 0.68% |
Dividend Analysis & Yield Comparison: Amedisys vs HCA Healthcare
| Metric | AMED | HCA |
|---|---|---|
| Last 12-Month Dividend | N/A | $2.04 |
| Last 12-Month Dividend Yield | N/A | 0.54% |
| 3-Year Avg Annual Dividend | N/A | $2.29 |
| 3-Year Avg Dividend Yield | N/A | 0.22% |
| 3-Year Total Dividends | N/A | $6.88 |
| Ex-Dividend Date | N/A | Mar 17, 2025 |